{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:12:47Z","timestamp":1791475967923,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Yuhan Corporation and the Ministry of Science","award":["IITP-2024-RS-2022-00156439"],"award-info":[{"award-number":["IITP-2024-RS-2022-00156439"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Telmisartan exhibits superior efficacy in controlling 24-h blood pressure (BP) compared with other angiotensin receptor blockers (ARBs). However, data on its cardiovascular effects in patients with hypertension are limited. This study aimed to evaluate the cardiovascular outcomes in patients taking telmisartan compared to those taking other ARBs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This multicenter retrospective study used data from the Korea University Medical Center database, built from electronic health records. A total of 19,247 patients taking two or more antihypertensive medications were identified. Patients prescribed telmisartan (telmisartan users) were compared with those prescribed an ARB other than telmisartan (other ARB users). The primary outcome was major adverse cardiac events (MACE), a composite of cardiovascular death, myocardial infarction, stroke, and hospitalizations due to heart failure. The adjusted outcomes were compared using 1:1 propensity score (PS) matching.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Overall, 3,437 (17.9%) patients were telmisartan users. These patients were more likely to be younger and male and less likely to have a history of chronic kidney disease, dialysis, or heart failure. In the PS-matched cohort, BP control was similar in both groups; however, telmisartan users exhibited significantly lower visit-to-visit BP variability. The adjusted 3-year MACE rate was similar between telmisartan users (4.6%) and other ARB users (4.7%, log-rank P\u2005=\u20050.75), with comparable safety profiles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In real-world practice, telmisartan showed cardiovascular outcomes similar to those of other ARBs in patients with hypertension taking two or more antihypertensive drugs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpae012","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T18:05:49Z","timestamp":1706551549000},"page":"429-437","source":"Crossref","is-referenced-by-count":7,"title":["Three-Year Cardiovascular Outcomes of Telmisartan in Patients With Hypertension: An Electronic Health Record-Based Cohort Study"],"prefix":"10.1093","volume":"37","author":[{"given":"Yunjin","family":"Yum","sequence":"first","affiliation":[{"name":"Department of Biostatistics, Korea University College of Medicine , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-0891","authenticated-orcid":false,"given":"Ju Hyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Joon","family":"Joo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital , Seoul , Republic of Korea"},{"name":"Department of Medical Informatics, Korea University College of Medicine , Seoul , Republic of Korea"},{"name":"Korea University Research Institute for Medical Bigdata Science, College of Medicine, Korea University , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Korea University Ansan Hospital , Ansan , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Ju","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"2024051505511468600_CIT0001","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/VHRM.S23468","article-title":"Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk","volume":"7","author":"Farsang","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"2024051505511468600_CIT0002","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"Strauss","year":"2006","journal-title":"Circulation"},{"key":"2024051505511468600_CIT0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2024051505511468600_CIT0004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024051505511468600_CIT0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2024051505511468600_CIT0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs\u2014overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J Hypertens"},{"key":"2024051505511468600_CIT0007","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/S0895-7061(99)00250-2","article-title":"Newly emerging pharmacologic differences in angiotensin II receptor blockers","volume":"13","author":"Oparil","year":"2000","journal-title":"Am J Hypertens"},{"key":"2024051505511468600_CIT0008","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1389450120666190821152000","article-title":"Angiotensin type 1 receptor blockers in heart failure","volume":"21","author":"Singh","year":"2020","journal-title":"Curr Drug Targets"},{"key":"2024051505511468600_CIT0009","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1021\/acs.jcim.7b00424","article-title":"Divergent spatiotemporal interaction of angiotensin receptor blocking drugs with angiotensin type 1 receptor","volume":"58","author":"Singh","year":"2018","journal-title":"J Chem Inf Model"},{"key":"2024051505511468600_CIT0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1524-6175.2003.01612.x","article-title":"Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database","volume":"5","author":"Neutel","year":"2003","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2024051505511468600_CIT0011","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2310\/JIM.0b013e31820bf26b","article-title":"Telmisartan improves insulin resistance in patients with low cytokine levels","volume":"59","author":"Sanchez Munoz-Torrero","year":"2011","journal-title":"J Investig Med"},{"key":"2024051505511468600_CIT0012","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2024051505511468600_CIT0013","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.1097\/MJT.0000000000000733","article-title":"Telmisartan improves insulin resistance: a meta-analysis","volume":"25","author":"Wang","year":"2018","journal-title":"Am J Ther"},{"key":"2024051505511468600_CIT0014","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"2024051505511468600_CIT0015","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000000154","article-title":"Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis","volume":"32","author":"Foulquier","year":"2014","journal-title":"J Hypertens"},{"key":"2024051505511468600_CIT0016","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"2024051505511468600_CIT0017","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2024051505511468600_CIT0018","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2024051505511468600_CIT0019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"key":"2024051505511468600_CIT0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"2024051505511468600_CIT0021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/ecp.10.141","article-title":"Telmisartan for the reduction of cardiovascular morbidity and mortality","volume":"4","author":"Verdecchia","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024051505511468600_CIT0022","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/hr.2009.131","article-title":"Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy","volume":"32","author":"Masuda","year":"2009","journal-title":"Hypertens Res"},{"key":"2024051505511468600_CIT0023","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/hr.2010.67","article-title":"Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy","volume":"33","author":"Sukumaran","year":"2010","journal-title":"Hypertens Res"},{"key":"2024051505511468600_CIT0024","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ajh\/hpt188","article-title":"Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure","volume":"27","author":"Kishi","year":"2014","journal-title":"Am J Hypertens"},{"key":"2024051505511468600_CIT0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1524-6175.2005.05264.x","article-title":"The pleiotropic effects of angiotensin receptor blockers","volume":"8","author":"Chrysant","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2024051505511468600_CIT0026","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1742-1241.2009.02028.x","article-title":"Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach","volume":"63","author":"Nixon","year":"2009","journal-title":"Int J Clin Pract"},{"key":"2024051505511468600_CIT0027","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ajh\/hpu076","article-title":"Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity","volume":"27","author":"Sueta","year":"2014","journal-title":"Am J Hypertens"},{"key":"2024051505511468600_CIT0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/hr.2013.121","article-title":"Effect of telmisartan vs. ramipril on \u201cdipping\u201d status and blood pressure variability: pooled analysis of the PRISMA studies","volume":"37","author":"Gosse","year":"2014","journal-title":"Hypertens Res"},{"key":"2024051505511468600_CIT0029","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ajh\/hpw157","article-title":"Impact of visit-to-visit variability in systolic blood pressure on cardiovascular outcomes in Korean National Health insurance service-national sample cohort","volume":"30","author":"Choi","year":"2017","journal-title":"Am J Hypertens"},{"key":"2024051505511468600_CIT0030","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/HYPERTENSIONAHA.117.09714","article-title":"Relative and combined prognostic importance of on-treatment mean and visit-to-visit blood pressure variability in ONTARGET and TRANSCEND patients","volume":"70","author":"Mancia","year":"2017","journal-title":"Hypertension"},{"key":"2024051505511468600_CIT0031","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ajh.2011.34","article-title":"Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome","volume":"24","author":"Khan","year":"2011","journal-title":"Am J Hypertens"},{"key":"2024051505511468600_CIT0032","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/HYPERTENSIONAHA.111.176263","article-title":"Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-\u03b3\/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade","volume":"59","author":"Kusunoki","year":"2012","journal-title":"Hypertension"},{"key":"2024051505511468600_CIT0033","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000506796","article-title":"Telmisartan protects auditory hair cells from gentamicin-induced toxicity in vitro","volume":"25","author":"Cortada","year":"2020","journal-title":"Audiol Neurootol"},{"key":"2024051505511468600_CIT0034","doi-asserted-by":"crossref","first-page":"e0188596","DOI":"10.1371\/journal.pone.0188596","article-title":"Effects of peroxisome proliferator activated receptors (PPAR)-\u03b3 and -\u03b1 agonists on cochlear protection from oxidative stress","volume":"12","author":"Sekulic-Jablanovic","year":"2017","journal-title":"PLoS One"},{"key":"2024051505511468600_CIT0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40256-016-0185-0","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on prothrombotic processes and myocardial infarction risk","volume":"16","author":"Dezsi","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"2024051505511468600_CIT0036","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"82","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024051505511468600_CIT0037","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40256-015-0140-5","article-title":"Affiliations comparative effectiveness of angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors following contemporary treatments in patients with acute myocardial infarction: results from the Korean Working Group in Myocardial Infarction (KorMI) registry","volume":"15","author":"Song","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"2024051505511468600_CIT0038","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcard.2019.11.086","article-title":"Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention","volume":"306","author":"Ann","year":"2020","journal-title":"Int J Cardiol"},{"key":"2024051505511468600_CIT0039","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40885-023-00243-8","article-title":"Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Hypertens"},{"key":"2024051505511468600_CIT0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000489855","article-title":"Methods of blood pressure assessment used in milestone hypertension trials","volume":"6","author":"Chen","year":"2018","journal-title":"Pulse (Basel)"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpae012\/56618231\/hpae012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/6\/429\/57314095\/hpae012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/6\/429\/57314095\/hpae012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:32:22Z","timestamp":1715758342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/37\/6\/429\/7591421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpae012","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,1,29]]}}}